刘志华,马晨光.缺血性心肌病不同阶段基因表达的改变模式研究[J].集成技术,2017,6(5):69-75
缺血性心肌病不同阶段基因表达的改变模式研究
Altered Gene Expression Through Different Stages of IschemicCardiomyopathy
投稿时间: 2017-08-01  最后修改时间: 2017-08-14
DOI:
中文关键词:  缺血性心肌病;生物信息学;生物标志物;微阵列;转录组
英文关键词:ischemic cardiomyopathy; bioinformatics; biomarker; microarray; transcriptome
基金项目:北京市科技新星计划资助(Z141102001814075);深圳市科技计划(JCYJ20150401145529007)
作者单位
刘志华 中国科学院深圳先进技术研究院 深圳 518055;北京易咨众科科技有限公司 北京 100084 
马晨光 北京易咨众科科技有限公司 北京 100084 
摘要点击次数: 57
全文下载次数: 85
中文摘要:
      文章选取缺血性心肌病患者和对照组收集的外周血,对其采用微阵列数据集进行转录组分析, 分为两个部分进行。在第一部分,从 3 组缺血性心肌病患者样本与健康对照的数据集分析中,确定了 3 个重要基因——成纤维细胞生长因子结合蛋白 2(FGFBP2)、葡萄糖-果糖氧化还原酶结构域(GFOD1)和 伴皮层下囊肿的巨脑性白质脑病(MLC1),可作为潜在的 mRNA 生物标志物。在第二部分,从 3 个时间 点(发作当天、恢复 4~6 天及恢复 6 个月)收集了 2 组基因表达数据集。基因代谢途径的差异性分析表 明,与对照组对比,发作组和恢复组涉及到炎症和免疫途径;与恢复 6 个月组对比,发作组和恢复组 (4~6 天)涉及到代谢途径或神经分泌。这显示了缺血性心肌病的发作和恢复期间的生物学过程变化。实 验结果表明,3 种潜在的 mRNA 生物标志物——FGFBP2、GFOD1 和 MLC1,涉及到缺血性心肌病不同 的代谢通路,具有连续的生物学过程变化。
英文摘要:
      In this study, transcriptome analysis was conducted on the microarray data sets of peripheral blood collected from patients with ischemic cardiomyopathy and controls. The analysis was carried out in two phases. In phase 1, by comparing three sets of ischemic cardiomyopathy samples versus healthy controls, we identified three key genes—fibroblast growth factor binding protein 2 (FGFBP2), glucose-fructose oxidoreductase domain containing 1 (GFOD1), and megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1). These were considered as the potential mRNA biomarkers candidates. In phase 2, two gene expression data sets were collected on three points in time (the day of attack, 4-6 days of recovery, and 6 months of recovery). Differential analysis of gene pathways revealed that the seizure and recovery group were involved in the inflammatory and immune pathways compared with the control group. The seizure and recovery group (4-6 days) were involvedin the metabolic pathways or nerve secretion compared with the 6 months of recovery group. The experimental results show that the three potential mRNA biomarkers (FGFBP2, GFOD1 and MLC1) can be involved different pathways of ischemic cardiomyopathy, exhibiting continuous changes in the biological process.
查看全文  查看/发表评论  下载PDF阅读器
关闭
微信关注二维码 用微信扫一扫

美女

美女图片

美女

美女图片